The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
MASSDEVICE ON CALL — Bad timing and a financial crisis nearly buried MVRx and its mitral valve repair technology forever, but the company’s founders finally revealed their progress over the weekend at the Transcatheter Cardiovascular Therapeutics conference.
Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.
A group of medtech insiders gathered in Boston last night to talk shop, share stories and glean insight from some of the industry’s brightest minds at MassDevice’s DeviceTalks East conference.
Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.
Results from the 1st patients treated with CardioKinetix’s Parachute implant suggest that the device may be able to help reshape the heart following a heart attack, improving pumping.
